---
schema_version: "secwatch.filing_event.v1"
accession: "0001826667-25-000007"
form_type: "8-K"
ticker: "TLSI"
cik: "0001826667"
company_name: "TriSalus Life Sciences, Inc."
filed_at: "2025-01-23T23:59:59+00:00"
generated_at: "2026-05-27T15:28:35.667832+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# TriSalus Q4 rev $8.3M (+44% YoY), FY2024 rev $29.4M (+59% YoY); guides to positive EBITDA in 2025

## Summary
- Q4 2024 revenue ~$8.3M, up 44% YoY; FY2024 revenue ~$29.4M, up 59% YoY.
- Q4 operating cash flow (~$5.6M) improved from (~$10.8M) in Q3.
- Expects positive full-year EBITDA in 2025 and positive cash flow during H2 2025.
- Cash ~$8.5M; expects to qualify for additional $10M debt tranche from OrbiMed in Q1 2025.
- Revenue growth guidance for 2025: in excess of 50%.

## SEC filing metadata
- accession: 0001826667-25-000007
- form_type: 8-K
- ticker: TLSI
- cik: 0001826667
- company_name: TriSalus Life Sciences, Inc.
- filed_at: 2025-01-23T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826667/000182666725000007/0001826667-25-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826667/000182666725000007/tlsi-20250123.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001826667-25-000007
- JSON: https://secwatch.observer/filing/0001826667-25-000007.json
- Plain text: https://secwatch.observer/filing/0001826667-25-000007.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.